6-fluoro-5-(chloroacetyl)oxindole | 118307-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-fluoro-5-(chloroacetyl)oxindole
• 英文别名: 5-(2-Chloroacetyl)-6-fluoroindolin-2-one；5-(2-chloroacetyl)-6-fluoro-1,3-dihydroindol-2-one
• CAS: 118307-02-1
• 化学式: C₁₀H₇ClFNO₂
• 分子量: 227.622
• InChiKey: OVCHPNNWSXUAFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-fluoro-5-(chloroacetyl)oxindole 在 三乙基硅烷 、 sodium carbonate 、 三氟乙酸 、 sodium iodide 作用下， 以 various solvent(s) 为溶剂， 反应 72.0h， 生成 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazinyl]ethyl}-6-fluoro-1,3-dihydro-2(1H)-indol-2-one
  参考文献：
  名称：

  3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents

  摘要：

  A series of substituted phenethyl derivatives of 3-benzisothiazolylpiperazine incorporating potent D-2 and 5-HT2A antagonist activity was investigated as an approach to a novel atypical antipsychotic agent. The in vitro profile of 8e from this series is a combination of D-2 receptor affinity comparable to the typical antipsychotic agent haloperidol and a 5-HT2A/D-2 ratio comparable to the atypical agent clozapine. In vivo 8e possesses activity consistent with an efficacious antipsychotic agent with less tendency to induce extrapyramidal side effects in man.

  DOI：

  10.1021/jm950625l
• 作为产物：
  描述：

  氯乙酰氯 以96%的产率得到
  参考文献：
  名称：

  LOWE, JOHN A. (III);NAGEL, ARTHUR A.

  摘要：

  DOI：

文献信息

• Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
  申请人：Ortuno Jean-Claude

  公开号：US20110034460A1

  公开（公告）日：2011-02-10

  Compounds of formula (I): wherein: m and n represent 1 or 2, A represents a pyrrolyl group, X represents a C(O), S(O) or SO 2 group, R 1 and R 2 represent an alkyl group or, together with the nitrogen atom carrying them, form a heterocyclic group, R 3 and R 4 , together with the atoms carrying them, form a heterocyclic group, R 5 represents a hydrogen atom or an alkyl group, R 6 represents a hydrogen atom or a halogen atom. Medicinal products containing the same which are useful in treating cancer.

  式（I）的化合物： 其中： m和n代表1或2， A代表吡咯基， X代表C（O）、S（O）或SO2基团， R1和R2代表烷基或与携带它们的氮原子一起形成杂环基团， R3和R4与携带它们的原子一起形成杂环基团， R5代表氢原子或烷基， R6代表氢原子或卤素原子。 含有这些化合物的药物，可用于治疗癌症。
• METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY
  申请人：——

  公开号：US20020004504A1

  公开（公告）日：2002-01-10

  A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula 1 or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined in the specification.

  在哺乳动物中治疗青光眼和缺血性视网膜病的方法，包括向所述哺乳动物施用公式1的化合物或其药学上可接受的酸盐的治疗有效量，其中n、X、Y和Ar如规范中定义。
• Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study
  作者：Jing Guo、Mingyue Zhu、Tianxiao Wu、Chenzhou Hao、Kai Wang、Zizheng Yan、Wanxu Huang、Jian Wang、Dongmei Zhao、Maosheng Cheng

  DOI：10.1016/j.bmc.2017.04.047

  日期：2017.7

  cells. Western blot analysis indicated that compound 12g potently inhibited the PAK4/LIMK1/cofilin signalling pathways. Finally, the binding mode between compound 12g with PAK4 was proposed by molecular docking. A preliminary ADME profile of the compound 12g was also drawn on the basis of QikProp predictions.

  利用药效基团杂交方法，设计，合成并评估了一系列新的取代的吲哚啉-2-酮衍生物对p21活化激酶4的体外生物学活性。化合物11b，12d和12g对PAK4的抑制作用最强（IC 50分别 为22 nM，16 nM和27 nM）。其中，化合物12g对A549细胞表现出最高的抗增殖活性（IC 50  = 0.83μM）。A549细胞的凋亡分析表明该化合物为12g通过将细胞停滞在细胞周期的G2 / M期来延迟细胞周期进程，从而延缓细胞生长。进一步的研究表明，化合物12g强烈抑制A549细胞的迁移和侵袭。Western印迹分析表明化合物12g有效抑制PAK4 / LIMK1 / cofilin信号传导途径。最后，通过分子对接提出了化合物12g与PAK4的结合方式。还根据QikProp预测得出了化合物12g的ADME初步概况。
• Anxiety treatments with ziprasidone
  申请人：Romano Joseph Steven

  公开号：US20050004138A1

  公开（公告）日：2005-01-06

  The present invention, in one aspect, relates to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for treating, in a mammal, including a human, situational anxiety, for example, anxiety experienced prior to medical procedures (e.g., surgery), public speaking, anxiety associated with swimming or water, anxiety associated with travel (e.g., air travel), or anxiety associated with specific phobias (snakes, spider, rats, sight of blood), comprising administering a pharmaceutically effective amount of a compound of formula I to the mammal. In another aspect, the present invention is directed to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for treating, in a mammal, including a human, treatment-resistant anxiety, which method comprises administering a pharmaceutically effective amount of a compound of formula I to the mammal. The compounds of formula I are defined as follows: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined.

  本发明在某些方面涉及使用以下式子定义的哌嗪基-杂环化合物的方法，用于治疗哺乳动物，包括人类的情境焦虑，例如在医疗程序（例如手术）、公共演讲、与游泳或水有关的焦虑、与旅行（例如空中旅行）有关的焦虑或与特定恐惧症（蛇、蜘蛛、老鼠、血液视觉）有关的焦虑，包括向哺乳动物投与化学有效量的式子I的化合物。在另一个方面，本发明涉及使用以下式子定义的哌嗪基-杂环化合物的方法，用于治疗哺乳动物，包括人类的难治性焦虑，其中该方法包括向哺乳动物投与化学有效量的式子I的化合物。式子I的化合物定义如下：或其药学上可接受的酸盐，其中Ar、n、X和Y如上定义。
• Treatment of bipolar disorders and associated symptoms
  申请人：Romano Joseph Steven

  公开号：US20050038036A1

  公开（公告）日：2005-02-17

  The present invention relates to a method for treatments relating to bipolar disorder in a mammal, including a human, the treatments including treatment of rapid-cycling bipolar disorder, treatment of symptoms of bipolar disorder selected from the group consisting of acute mania and depression, treatment for effecting mood stabilization; treatment for preventing relapse into bipolar episodes, and for the treatment of suicidal thoughts and tendencies associated with bipolar disorder, comprising administering to said mammal an effective amount of a compound of the formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined.

  本发明涉及一种治疗哺乳动物（包括人类）的双相障碍的方法，包括治疗快速循环型双相障碍，治疗选自急性躁狂和抑郁症状的双相障碍症状，治疗以影响情绪稳定为目的的治疗，预防双相障碍复发的治疗，以及治疗与双相障碍相关的自杀思想和倾向。该方法包括向该哺乳动物施用以下化合物的有效量：式I的化合物或其药学上可接受的酸盐加合物，其中Ar、n、X和Y如定义。